Oppenheimer Maintains a Buy Rating on Celsion Corp (CLSN)

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Celsion Corp (CLSN). The company’s shares opened today at $2.15.

According to TipRanks.com, Singh is a 4-star analyst with an average return of 3.3% and a 48.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.

Celsion Corp has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.48 and a one-year low of $1.35. Currently, Celsion Corp has an average volume of 139.8K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLSN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.